炎症性肠病妊娠期与哺乳期生物制剂及口服小分子药物治疗的药理学管理
炎症性肠病常累及育龄期人群,患者因担忧药物对受孕、胎儿及哺乳的影响而依从性不佳。抗TNF生物制剂英夫利西单抗和阿达木单抗在妊娠期研究充分,未增加先天畸形或胎儿死亡风险;其他抗TNF药物及维得利珠单抗、乌司奴单抗临床数据有限但暂无显著安全信号;托法替布动物实验有致畸性,备孕患者禁用。
要点
- 英夫利西单抗和阿达木单抗妊娠期未增加先天畸形或胎儿死亡风险
- 英夫利西单抗和阿达木单抗入母乳量极少,被婴儿消化系统蛋白水解,无报道短期或长期不良效应
- 托法替布动物模型有致畸性,备孕患者禁用
核心结论
- 多数炎症性肠病治疗药物在妊娠期安全,停药可致疾病活动并关联不良母胎结局。
- 英夫利西单抗和阿达木单抗妊娠期未增加先天畸形或胎儿死亡风险,入母乳量极少且无报道不良效应。
- 托法替布动物模型有致畸性,备孕患者禁用。
研究设计与样本
- 综述,聚焦炎症性肠病合并妊娠、备孕及哺乳期生物制剂与口服小分子治疗的药理学管理。
主要发现
- 英夫利西单抗和阿达木单抗在妊娠第二、三期主动经胎盘转运,但未增加先天畸形或胎儿死亡发生率。
- 英夫利西单抗和阿达木单抗转运至母乳量极少,被婴儿消化系统蛋白水解,无报道短期或长期不良效应。
- 其他获批抗TNF药物及维得利珠单抗、乌司奴单抗临床数据匮乏,但迄今无显著安全信号记录。
- 托法替布在动物模型中有致畸性,备孕患者禁用。
关键数值与推荐
- 英夫利西单抗和阿达木单抗:妊娠第二、三期主动经胎盘转运,未增加先天畸形或胎儿死亡风险。
- 英夫利西单抗和阿达木单抗:入母乳量极少,被婴儿消化系统蛋白水解,无报道短期或长期不良效应。
- 托法替布:动物模型有致畸性,备孕患者禁用。
临床怎么用
- 备孕、妊娠及哺乳期炎症性肠病患者应知晓多数药物安全,避免因担忧而自行停药导致疾病活动。
- 英夫利西单抗和阿达木单抗可在妊娠期继续使用,哺乳期也可使用。
- 托法替布禁用于备孕患者。
- 其他抗TNF药物及维得利珠单抗、乌司奴单抗数据有限,使用时应个体化评估。
局限性
- 其他获批抗TNF药物及维得利珠单抗、乌司奴单抗的临床数据匮乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The inflammatory bowel diseases commonly affect individuals during their peak reproductive years. Patients are often concerned about the impact of medical therapies on their ability to conceive, effect on the fetus, as well as the ability to breastfeed, which has led to poor medical adherence during pregnancy. However, most medications are safe, and discontinuation may lead to active disease, which is associated with adverse materno-fetal outcomes. The anti-TNF biologic therapies, infliximab and adalimumab have been extensively studied in the context of pregnancy. They are actively transferred to the placenta during the second and third trimesters; these have not been associated with an increased rate of congenital abnormalities or fetal death. The minimal amounts of drug that are transferred to breast milk are proteolyzed by the infant's digestive system with no reported short- or long-term adverse effects. There is a paucity of clinical data for the other approved anti-TNF agents or newer anti-integrin (vedolizumab) and anti-interleukin (ustekinumab) therapies used in the management of inflammatory bowel disease; however, no significant safety signals have been documented thus far. The new oral small molecule therapy, tofacitinib is teratogenic in animal models and is contra-indicated in patients attempting pregnancy. It is important that patients, as well as physicians managing patients with these conditions, be aware of the impact of these medical therapies during pregnancy.
引用
- Picardo S, Seow CH. A Pharmacological Approach to Managing Inflammatory Bowel Disease During Conception, Pregnancy and Breastfeeding: Biologic and Oral Small Molecule Therapy. Drugs. 2019. PMID: 31183768. doi:10.1007/s40265-019-01141-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。